{
    "clinical_study": {
        "@rank": "90887", 
        "acronym": "STATVAS", 
        "arm_group": [
            {
                "arm_group_label": "Group I", 
                "arm_group_type": "Experimental", 
                "description": "Rosuvastatin 20 mg/day"
            }, 
            {
                "arm_group_label": "Group II", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether rosuvastatin could reduce the subclinical\n      markers of atherosclerosis and the incidence of major cardiovascular events in patients with\n      primary necrotizing vasculitides."
        }, 
        "brief_title": "Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "ANCA-associated Primary Necrotizing Vasculitides", 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Vasculitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Previous studies demonstrated the presence of subclinical atherosclerosis in patients with\n      ANCA-associated systemic necrotizing vasculitis. Since statins lower levels of inflammatory\n      proteins and cholesterol, we hypothesized that people with ANCA-associated systemic\n      necrotizing vasculitis but without indication for statin treatment according to\n      recommandations might benefit from statin treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patient > 18 years. ANCA-associated vasculitis: granulomatosis with polyangiitis (GPA),\n        microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA,\n        Churg-Strauss syndrome).\n\n        Patients will fulfill the Chapel Hill Consensus Criteria and the American College of\n        Rheumatology criteria, in remission of vasculitis.\n\n        Patients in remission of vasculitis after induction therapy (for first flare or relapse),\n        including corticosteroids associated or not with immunosuppressive agents according to\n        Good Clinical Practice for the treatment of vasculitis, and at least 6 months after the\n        beginning of induction therapy.\n\n        Patients with informed and signed consent\n\n        Exclusion Criteria:\n\n        Other systemic vasculitis. Secondary vasculitis (paraneoplastic or infectious). Patient\n        with active vasculitis after induction therapy, requiring salvage therapy.\n\n        Inability to sign informed consent. Inability to take the experimental treatment.\n        Hypersensitivity to rosuvastatin or to any of the excipients. Pregnancy. Chronic HCV, HBV\n        and/or HIV infection. Patient receiving other statin or other hypolipemic agent. Patient\n        requiring treatment with statin according to Afssaps recommandations published in 2005 as\n        primary or secondary prevention."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117453", 
            "org_study_id": "P120127", 
            "secondary_id": "2013-002531-15"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group I", 
                "description": "Rosuvastatin 20 mg/day", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group II", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ANCA vasculitis", 
            "Statin", 
            "Subclinical markers of atherosclerosis", 
            "Cardiovascular events", 
            "Myocardial infarction", 
            "Stroke", 
            "Arterial revascularization", 
            "Unstable angina", 
            "Death"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides", 
        "overall_contact": {
            "email": "benjamin.terrier@cch.aphp.fr", 
            "last_name": "Benjamin Terrier, MD, PhD", 
            "phone": "+ 33 1 58 41 14 61"
        }, 
        "overall_contact_backup": {
            "email": "laurence.lecomte@nck.aphp.fr", 
            "last_name": "Laurence Lecomte, PhD", 
            "phone": "+33 1 71 19 64 94"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessed with B-mode ultrasound", 
            "measure": "Rate of change in mean carotid intima-media thickness for 12 predefined sites", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117453"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessed with B-mode ultrasound", 
                "measure": "Rate of change in endothelial function with brachial artery flow-mediated dilatation", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Assessed with B-mode ultrasound", 
                "measure": "Rate of change in the number of plaques in three peripheral vessels (carotid and femoral arteries and abdominal aorta)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "ultra-sensitive CRP, VCAM-1, P-selectin, thrombomodulin, circulating endothelial, platelet and leucocytes microparticles", 
                "measure": "Rate of change in serum biomarkers of subclinical atherosclerosis", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Rate of major cardiovascular events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "BVAS", 
                "measure": "Rate of change in vasculitis activity", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Rate of vasculitis relapses", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Rate of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}